Jaeseung Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jaeseung Kim has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Adam C. Smith
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
1 shared publication- Adrian M. Dubuc
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
1 shared publication - Amir Tahmasb Fathi
Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States
1 shared publication Amyah C. Harris
Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
1 shared publicationAnthony J. Iafrate
10Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
1 shared publicationAnthony Schmitt
Arima Genomics Inc., Carlsbad, CA
1 shared publication
Latest Publications
- Open Access
- 26 February 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (5) , 1003-1012
Integrative cytogenetic and molecular studies unmask “chromosomal mimicry” in hematologic malignancies
The detection of structural variants (SVs) represents a critical component in the diagnostic evaluation and treatment of many hematologic malignancies. Although clinical SV testing mainly consists of traditional cytogenetic methodologies, technological innovations have led to alternative approaches with improved resolution. In this study, we sought to characterize the clinical impact of targeted RNA sequencing on the diagnosis of myeloid and immature lymphoid malignancies. Across a cohort (n = 380) of myeloid (87%) and immature lymphoid (13%) tumors, we compared SVs detected by chromosome banding analysis (CBA) and fusion events detected by anchored multiplex polymerase chain reaction (AMP)–targeted RNA sequencing. Variants detected by either assay were categorized using a 5-tier system: tier 1 (established clinical significance); tier 2 (possible clinical significance); tier 3 (unknown significance); tier 4 (known germ line variants), and tier 5 (no variants detected). The combined use of AMP and CBA improved the detection of clinically relevant (tier 1 or 2) findings in 10% of cases. Unexpectedly, in 1% (3/380) of the patients in our study, CBA appeared to detect a defining SV, for example, t(9;22)(q34;q11.2), that was not confirmed by AMP fusion studies. Subsequent evaluation by orthogonal approaches confirmed breakpoints on the expected chromosomes but did not involve the anticipated genes. Our study indicates that “chromosomal mimicry,” a phenomenon in which chromosome morphology resembles a known SV but lacks the expected gene-level rearrangement, is an infrequent but recurrent finding with the potential to confound clinical management. Our study highlights the need for assays with gene-level resolution in the diagnostic evaluation of hematologic malignancies.
- 26 February 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (5) , 1003-1012
Open AccessIntegrative cytogenetic and molecular studies unmask “chromosomal mimicry” in hematologic malignancies
The detection of structural variants (SVs) represents a critical component in the diagnostic evaluation and treatment of many hematologic malignancies. Although clinical SV testing mainly consists of traditional cytogenetic methodologies, technological innovations have led to alternative approaches with improved resolution. In this study, we sought to characterize the clinical impact of targeted RNA sequencing on the diagnosis of myeloid and immature lymphoid malignancies. Across a cohort (n = 380) of myeloid (87%) and immature lymphoid (13%) tumors, we compared SVs detected by chromosome banding analysis (CBA) and fusion events detected by anchored multiplex polymerase chain reaction (AMP)–targeted RNA sequencing. Variants detected by either assay were categorized using a 5-tier system: tier 1 (established clinical significance); tier 2 (possible clinical significance); tier 3 (unknown significance); tier 4 (known germ line variants), and tier 5 (no variants detected). The combined use of AMP and CBA improved the detection of clinically relevant (tier 1 or 2) findings in 10% of cases. Unexpectedly, in 1% (3/380) of the patients in our study, CBA appeared to detect a defining SV, for example, t(9;22)(q34;q11.2), that was not confirmed by AMP fusion studies. Subsequent evaluation by orthogonal approaches confirmed breakpoints on the expected chromosomes but did not involve the anticipated genes. Our study indicates that “chromosomal mimicry,” a phenomenon in which chromosome morphology resembles a known SV but lacks the expected gene-level rearrangement, is an infrequent but recurrent finding with the potential to confound clinical management. Our study highlights the need for assays with gene-level resolution in the diagnostic evaluation of hematologic malignancies.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 416
Abstract 416: A novel non-covalent and rapidly reversible proteasome inhibitor for multiple myeloma and various solid cancers
The existing proteasome inhibitors, such as bortezomib and ixazomib, are effective in multiple myeloma, but have little activity against solid tumors. These are covalent boronic acid-based compounds and are associated with undesired side effects, mainly hematologic toxicity and peripheral neuropathy. A variety of improved covalent proteasome inhibitors have been developed, but lack of oral availability and low distribution in tumors make them ineffective in solid tumors. In addition, they still have a narrow therapeutic window due to unexpected adverse effects such as cardiac and pulmonary toxicity. We report a non-covalent and rapidly reversible proteasome inhibitor as a potential anti-cancer agent against solid tumors as well as multiple myeloma. These novel inhibitors, called QL compounds, are non-covalent chymotrypsin-like selective proteasome inhibitors that can be taken orally. They effectively inhibited tumor growth in multiple myeloma xenograft model without hematologic toxicity through improved PK properties, especially partition of compound between plasma and RBC. Moreover, this improved PK properties of the QL compounds allowed for sufficient distribution outside the blood compartment and induced tumor growth inhibition in some types of solid cancer xenograft models that were sensitive to proteasome inhibition. These results indicate that non-covalent and rapidly reversible proteasome inhibitors are an ideal strategy for multiple myeloma and potential agents for solid tumors. Citation Format: Won-Gyun Ahn, Yeejin Jeon, Yeong-In Yang, Jaeseung Kim, Seung-Joo Lee, Uwe Koch, Gunther Zischinsky, Axel Choidas, Ayesha Pasha, Bert Klebl, Robert Huber, Michael Hamacher, Kiyean Nam. A novel non-covalent and rapidly reversible proteasome inhibitor for multiple myeloma and various solid cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 416.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 416
Open AccessAbstract 416: A novel non-covalent and rapidly reversible proteasome inhibitor for multiple myeloma and various solid cancers
The existing proteasome inhibitors, such as bortezomib and ixazomib, are effective in multiple myeloma, but have little activity against solid tumors. These are covalent boronic acid-based compounds and are associated with undesired side effects, mainly hematologic toxicity and peripheral neuropathy. A variety of improved covalent proteasome inhibitors have been developed, but lack of oral availability and low distribution in tumors make them ineffective in solid tumors. In addition, they still have a narrow therapeutic window due to unexpected adverse effects such as cardiac and pulmonary toxicity. We report a non-covalent and rapidly reversible proteasome inhibitor as a potential anti-cancer agent against solid tumors as well as multiple myeloma. These novel inhibitors, called QL compounds, are non-covalent chymotrypsin-like selective proteasome inhibitors that can be taken orally. They effectively inhibited tumor growth in multiple myeloma xenograft model without hematologic toxicity through improved PK properties, especially partition of compound between plasma and RBC. Moreover, this improved PK properties of the QL compounds allowed for sufficient distribution outside the blood compartment and induced tumor growth inhibition in some types of solid cancer xenograft models that were sensitive to proteasome inhibition. These results indicate that non-covalent and rapidly reversible proteasome inhibitors are an ideal strategy for multiple myeloma and potential agents for solid tumors. Citation Format: Won-Gyun Ahn, Yeejin Jeon, Yeong-In Yang, Jaeseung Kim, Seung-Joo Lee, Uwe Koch, Gunther Zischinsky, Axel Choidas, Ayesha Pasha, Bert Klebl, Robert Huber, Michael Hamacher, Kiyean Nam. A novel non-covalent and rapidly reversible proteasome inhibitor for multiple myeloma and various solid cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 416.
- Open Access
- 1 September 2005
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 70 (20) , 8122-8129
Preparation and Analysis of Oligonucleotides Containing the C4‘-Oxidized Abasic Site and Related Mechanistic Probes
The C4‘-oxidized abasic site (C4-AP) is produced by a variety of DNA damaging agents. This alkali labile lesion can exist in up to four diastereomeric cyclic forms, in addition to the acyclic keto-aldehyde. Synthetic oligonucleotides containing the lesion were prepared from a stable photochemical precursor. Chemical integrity of the lesion containing oligonucleotides was probed using phosphodiesterase lability. Analysis of the 3‘,5‘-phosphate diester of the monomeric lesion released from single diastereomers of photolabile precursors by 1H NMR indicates that isomerization of the hemiacetal and/or hemiketal is rapid. The syntheses and characterization of oligonucleotides containing configurationally stable analogues of C4-AP, which serve as mechanistic probes for deciphering the structural basis of the biochemical and biological effects of the C4‘-oxidized abasic lesion, are also described.
- 1 September 2005
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 70 (20) , 8122-8129
Open AccessPreparation and Analysis of Oligonucleotides Containing the C4‘-Oxidized Abasic Site and Related Mechanistic Probes
The C4‘-oxidized abasic site (C4-AP) is produced by a variety of DNA damaging agents. This alkali labile lesion can exist in up to four diastereomeric cyclic forms, in addition to the acyclic keto-aldehyde. Synthetic oligonucleotides containing the lesion were prepared from a stable photochemical precursor. Chemical integrity of the lesion containing oligonucleotides was probed using phosphodiesterase lability. Analysis of the 3‘,5‘-phosphate diester of the monomeric lesion released from single diastereomers of photolabile precursors by 1H NMR indicates that isomerization of the hemiacetal and/or hemiketal is rapid. The syntheses and characterization of oligonucleotides containing configurationally stable analogues of C4-AP, which serve as mechanistic probes for deciphering the structural basis of the biochemical and biological effects of the C4‘-oxidized abasic lesion, are also described.